Cargando…

Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short?

Detalles Bibliográficos
Autores principales:	Mourikis, Philipp, Polzin, Amin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939072/ https://www.ncbi.nlm.nih.gov/pubmed/36645091 http://dx.doi.org/10.1161/JAHA.122.028775

Ejemplares similares

Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
por: Howard, Charles E., et al.
Publicado: (2019)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
por: Bainey, Kevin R., et al.
Publicado: (2023)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Antiplatelet Therapy and Percutaneous Coronary Interventions
por: Davanzo, Rene Hameau, et al.
Publicado: (2021)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
por: Hu, Mengjin, et al.
Publicado: (2022)

Intensity of antiplatelet therapy and percutaneous coronary intervention
por: Aronow, Wilbert S
Publicado: (2009)

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
por: Han, Jialun, et al.
Publicado: (2023)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion
por: Lee, Seung Hwa, et al.
Publicado: (2017)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease
por: Ostojic, Zvonimir, et al.
Publicado: (2021)

Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary Intervention
por: Greco, Antonio, et al.
Publicado: (2023)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Very Short Versus Longer Dual Antiplatelet Treatment After Coronary Interventions: A Systematic Review and Meta-analysis
por: Tsigkas, Grigorios, et al.
Publicado: (2022)

From Coronaries to Cirrhosis: The Role of Percutaneous Coronary Intervention and Dual Antiplatelet Therapy in End-Stage Liver Disease
por: Remillard, Taylor C., et al.
Publicado: (2021)

Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions
por: Summaria, Francesco, et al.
Publicado: (2015)

Long-Term Safety and Efficacy of Prolonged Dual Antiplatelet Therapy according to Baseline Anemia after Percutaneous Coronary Intervention
por: Kim, Hun-Tae, et al.
Publicado: (2022)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome: Practical lessons from a review
por: ten Berg, J. M., et al.
Publicado: (2017)

Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
por: Wisløff, Torbjørn, et al.
Publicado: (2016)

Percutaneous Coronary Intervention With Dual Antiplatelet Therapy in a Patient With Chronic Subdural Hematoma: Novel Approach
por: Etuk, Aniekeme S, et al.
Publicado: (2022)

Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Mohamed, Mohamed M. G., et al.
Publicado: (2022)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)

Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis
por: Han, Yan, et al.
Publicado: (2023)

The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”
por: Kang, Jeehoon, et al.
Publicado: (2018)

Extended Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Peripheral Arterial Disease: A Meta-Analysis
por: Ling, Hua, et al.
Publicado: (2018)

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis
por: Yin, Shang-He-Lin, et al.
Publicado: (2019)

Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis
por: Khan, Safi U., et al.
Publicado: (2020)

Comparison of 6-Month and Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Biodegradable Polymer Everolimus-Eluting Stent
por: Yoon, Yong-Hoon, et al.
Publicado: (2022)

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
por: Obayashi, Yuki, et al.
Publicado: (2022)

Risk of Postdischarge Bleeding From Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Among US Black and White Adults
por: Heindl, Brittain, et al.
Publicado: (2022)

Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
por: Wang, Huili, et al.
Publicado: (2015)

Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis
por: ZHOU, HONG, et al.
Publicado: (2013)

How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?
por: Cui, Kongyong, et al.
Publicado: (2022)

Income and antiplatelet adherence following percutaneous coronary intervention
por: LaRosa, Anna R., et al.
Publicado: (2022)

Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention
por: Gao, Song-Tao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jtorg8mt5valtmpisfe9jtiq06